Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs
Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs
复制标题
DOI：
10.1007/s00436-002-0769-2
复制
发表时间：
2003-06-01
影响因子：
2
通讯作者：
Kiderlen, AF
中科院分区：
文献类型：
--
作者：
Kayser, O;Olbrich, C;Kiderlen, AF
真正将新的抗寄生虫药物开发到市场水平是一件非常罕见的事情。大量的铅结构已经被筛选和丢弃，市场大而穷，行政壁垒越来越高和昂贵。新的抗寄生虫药物不仅必须更好，而且必须比现有的剧目更安全。药物开发有两个主要方面。一种是病原菌特异性生化干预策略，另一种是优化制定和应用策略。本文重点介绍了后者。在寻找和调整创新的和“智能的”，即针对寄生虫和疾病的配方和给药系统时，现有但有缺陷的药物可能会得到优化，以相对较低的成本提高其效率并减少负面副作用。此外，抗寄生虫药的低水溶性严重阻碍了许多有希望的新想法。在这里，下面讨论的一些创新的药物配方和给药系统可能提供高效的、技术上简单的解决方案。
The development of really new antiparasitic drugs to market level is a very rare event. A large number of lead structures have already been screened and discarded, the market is large but poor, and the administrative barriers are increasingly high and costly. Novel antiparasitics must not only be better, they must also be substantially safer than the existing repertoire. There are two major aspects to drug development. One is the strategy of pathogen-specific biochemical intervention, the other the strategy of optimal formulation and application. This review focuses on the latter. In finding and adapting innovative and "intelligent", i.e. parasite- and disease-specific formulations and delivery systems, established but deficient drugs might be optimised, enhancing their efficiency and reducing negative side effects at relatively low cost. Further, many promising new ideas are severely hampered by the low water solubility of the antiparasitic drug. Here as well, some of the innovative drug formulation and delivery systems discussed below might offer highly efficient, while technologically simple, solutions.